[{"orgOrder":0,"company":"CytRx Corporation","sponsor":"ImmunityBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Aldoxorubicin","moa":"DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase I","graph3":"CytRx Corporation","amount2":0.34000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.34000000000000002,"dosageForm":"","sponsorNew":"CytRx Corporation \/ ImmunityBio","highestDevelopmentStatusID":"6","companyTruncated":"CytRx Corporation \/ ImmunityBio"},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"Orphazyme","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Arimoclomol","moa":"HSF-1","graph1":"Neurology","graph2":"Phase III","graph3":"CytRx Corporation","amount2":0.12,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.12,"dosageForm":"Capsule","sponsorNew":"CytRx Corporation \/ Orphazyme A\/S","highestDevelopmentStatusID":"10","companyTruncated":"CytRx Corporation \/ Orphazyme A\/S"},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Aldoxorubicin","moa":"DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase II","graph3":"CytRx Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"CytRx Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CytRx Corporation \/ Not Applicable"},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"Orphazyme","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2020","type":"Public Offering","leadProduct":"Arimoclomol","moa":"Molecular chaperones","graph1":"Genetic Disease","graph2":"Phase III","graph3":"CytRx Corporation","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.080000000000000002,"dosageForm":"Capsule","sponsorNew":"CytRx Corporation \/ CytRx","highestDevelopmentStatusID":"10","companyTruncated":"CytRx Corporation \/ CytRx"},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"Aldoxorubicin HCl","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"CytRx Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension for Infusion","sponsorNew":"CytRx Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CytRx Corporation \/ Not Applicable"},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"ImmunityBio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"Aldoxorubicin HCl","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"CytRx Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension for Infusion","sponsorNew":"CytRx Corporation \/ ImmunityBio","highestDevelopmentStatusID":"8","companyTruncated":"CytRx Corporation \/ ImmunityBio"},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"NantKwest","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Aldoxorubicin HCl","moa":"DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase II","graph3":"CytRx Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"CytRx Corporation \/ NantKwest","highestDevelopmentStatusID":"8","companyTruncated":"CytRx Corporation \/ NantKwest"},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Arimoclomol","moa":"HSF-1","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"CytRx Corporation","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CytRx Corporation \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"CytRx Corporation \/ Not Applicable"},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Arimoclomol","moa":"Molecular chaperones","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"CytRx Corporation","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CytRx Corporation \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"CytRx Corporation \/ Not Applicable"},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Aldoxorubicin HCl","moa":"DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase II","graph3":"CytRx Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"CytRx Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CytRx Corporation \/ Not Applicable"},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Arimoclomol","moa":"HSP","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"CytRx Corporation","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CytRx Corporation \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"CytRx Corporation \/ Not Applicable"},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"ImmunityBio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Aldoxorubicin HCl","moa":"DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase II","graph3":"CytRx Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"CytRx Corporation \/ CytRx Corporation","highestDevelopmentStatusID":"8","companyTruncated":"CytRx Corporation \/ CytRx Corporation"},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Aldoxorubicin HCl","moa":"DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase II","graph3":"CytRx Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"CytRx Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CytRx Corporation \/ Not Applicable"},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Arimoclomol","moa":"Molecular chaperones","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"CytRx Corporation","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CytRx Corporation \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"CytRx Corporation \/ Not Applicable"},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"CytRx Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Merger","leadProduct":"Aldoxorubicin","moa":"DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase III","graph3":"CytRx Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"CytRx Corporation \/ CytRx Corporation","highestDevelopmentStatusID":"10","companyTruncated":"CytRx Corporation \/ CytRx Corporation"},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Aldoxorubicin","moa":"DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase III","graph3":"CytRx Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CytRx Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CytRx Corporation \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by CytRx Corporation

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : Aldoxorubicin, a rationally-engineered cytotoxic delivers well-established anti-cancer agent, doxorubicin, into tumor, utilizes an acid-sensitive linker that selectively binds to albumin, which may allow cytotoxic payload to preferentially accumulate in ...

                          Brand Name : INNO-206

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 20, 2022

                          Lead Product(s) : Aldoxorubicin

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : Through the merger with Centurion, the next-generation LADR drugs including INNO-206, are now within CytRx and poised for the last steps required for first-in-human studies, an achievement that could be expected to generate significant value for sharehol...

                          Brand Name : INNO-206

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          March 09, 2022

                          Lead Product(s) : Aldoxorubicin

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Recipient : Centurion BioPharma

                          Deal Size : Undisclosed

                          Deal Type : Merger

                          blank

                          03

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : CytRx’s drug candidate, arimoclomol, was sold to Orphazyme A/S in exchange for milestone payments and royalties. Orphazyme is developing arimoclomol in two indications, including Niemann-Pick disease Type C (NPC), and Gaucher disease.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          February 14, 2022

                          Lead Product(s) : Arimoclomol

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : ImmunityBio continues to study the effectiveness of N-803 and aldoxorubicin in combination with PD-L1 thaNK in Phase 1 / 2 clinical trials to treat triple negative breast cancer and head and neck cancer.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          December 21, 2021

                          Lead Product(s) : Aldoxorubicin HCl,PD-L1 t-haNK,Paclitaxel

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : Phase 2, study will evaluate the comparative efficacy and safety of standard-of-care chemotherapy versus standard-of-care chemotherapy, in combination with PD-L1 t-haNK, Anktiva (N-803), and aldoxorubicin in subjects with locally advanced or metastatic p...

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 13, 2021

                          Lead Product(s) : Aldoxorubicin HCl,Paclitaxel,Gemcitabine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Recipient : ImmunityBio

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : At 12-months, a significant treatment effect in favor of arimoclomol of −1.40 points was observed, corresponding to a 65% relative reduction in annual disease progression.

                          Brand Name : Miplyffa

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 24, 2021

                          Lead Product(s) : Arimoclomol

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : Enrollment of Cohort C, which includes Aldoxorubicin and patients who have previously failed two lines of standard-of-care therapy, is expected to be completed in the third quarter of 2021 and an early readout of survival data is expected in the first qu...

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          July 29, 2021

                          Lead Product(s) : Aldoxorubicin HCl,Paclitaxel,Avelumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : Orphazyme stated arimoclomol demonstrated a consistent safety profile throughout the 36-month treatment period. Arimoclomol is an investigational drug candidate that amplifies the production of heat-shock proteins (HSPs).

                          Brand Name : Miplyffa

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 29, 2021

                          Lead Product(s) : Arimoclomol

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : CytRx has received a Complete Response Letter from the U.S. Food and Drug Administration following its review of the new drug application for arimoclomol, a heat shock protein amplifier intended for the treatment of Niemann-Pick disease type C.

                          Brand Name : Miplyffa

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 18, 2021

                          Lead Product(s) : Arimoclomol

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : NantKwest and ImmunityBio’s QUILT 88 Trial shows novel combination immunotherapy, which includes which include CytRx’s licensed drug aldoxorubicin, has more than doubled historic median survival rates in patients.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          January 15, 2021

                          Lead Product(s) : Aldoxorubicin HCl,PD-L1 t-haNK,Paclitaxel

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : NantKwest

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank